share_log

BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate

BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate

BioNDVax 從吸入式 COVID-19 治療候選人身上吹捧了其他臨床前數據
Benzinga Real-time News ·  2023/01/23 11:52
  • BiondVax Pharmaceuticals Ltd (NYSE:BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug.
  • The study compared weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours before infection experienced no significant weight loss over the six-day trial.
  • But the untreated control group's weight declined 12% on average, a highly statistically significant difference.
  • The prophylactic results follow previously reported data from the same study indicating that compared to the control (placebo) group, hamsters treated with a 2mg dose of BiondVax's inhaled NanoAb one day after infection had negligible SARS-CoV-2 viral titers in their lungs, and experienced a milder and shorter illness in comparison to the placebo group that had at least 30-times higher viral titers.
  • This preclinical trial continues with additional arms testing lower therapeutic doses (0.66mg and 0.22mg). In 2023, BiondVax is expected to conduct a preclinical toxicity study.
  • The company also expects to scale up its manufacturing processes for NanoAbs for the first-in-human Phase 1/2a trial, which is planned for Q4 2023.
  • Price Action: BVXV shares are up 2.55% at $2.82 on the last check Monday.
  • 生德華製藥有限公司 紐約證券交易所代碼：BVXV）在其創新吸入式 NanoAB COVID-19 藥物的臨床前概念驗證研究中宣布了更多結果。
  • 該研究比較了兩組倉鼠的減肥。倉鼠在感染前三小時服用了 0.66 毫克劑量的 NanoAB，在六天的試驗中沒有明顯的體重減輕。
  • 但是，未經處理的對照組的體重平均下降了 12％，這在統計學上具有很大的顯著差異。
  • 預防性結果遵循同一研究先前報告的數據表明，與對照組（安慰劑）組相比，在感染的一天之後，用 2mg 劑量的 BiondPax 吸入 NanoAB 的 BioNanoAB 治療倉鼠相比，肺部中的 SARS-CoV-2 病毒滴度可忽略不計，並且與安慰劑組相比，病毒滴度至少 30 倍以上的安慰劑組相比，病毒滴度更輕，更短。
  • 該臨床前試驗繼續進行額外的武器測試，較低的治療劑量（0.66 毫克和 0.22 毫克）。2023 年，預計將進行臨床前毒性研究。
  • 該公司還預計將擴大其納米 ABS 的製造過程，以進行第一次人類的 1/2a 期試驗，該試驗計劃於 2023 年第四季度進行。
  • 價格行動： BVXV 的股票在星期一的最後一次檢查上漲了 2.55％，至 2.82 美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論